Clinical Trial Update: Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary Immunodeficiency [Phase 3]

View source ↗

Summary

Clinical trial evaluating IGSC 20% for primary immunodeficiency was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency

Drugs mentioned

• IGSC 20% (immunoglobulin G 20%)

Snippet

Sponsor: Grifols Therapeutics LLC | Conditions: Primary Immunodeficiency | Phase 3 | Status: WITHDRAWN